Sign inCreate account

Report workspace tools

NCT03851263WITHDRAWNanonymous

Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR).

Sponsor

Source record

ECRI bv

Phase

Source record

PHASE4

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Evolocumab

Indication / condition

AI-normalized

Coronary Artery Disease

Intervention

Source record

Evolocumab

Source & freshness

Source record

NCT ID

NCT03851263

Original source

ClinicalTrials.gov

Source last updated

Dec 06, 2019

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03851263

Title

Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR).

Sponsor

ECRI bv

Status

WITHDRAWN

Phase

PHASE4

Condition raw

Coronary Artery Disease

Condition normalized

Coronary Artery Disease

Modality raw

PCSK9

Modality normalized

monoclonal antibody

Target raw

Evolocumab

Target normalized

Evolocumab

Interventions

Evolocumab

Public preview

Source record

Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR). is a PHASE4 clinical asset sponsored by ECRI bv in Coronary Artery Disease. SEO and diligence focus: Evolocumab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR).

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03851263

Status

WITHDRAWN

Phase

PHASE4

Sponsor

ECRI bv

Executive brief

Investment-Ready Snapshot

Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR). is a PHASE4 clinical asset sponsored by ECRI bv in Coronary Artery Disease. SEO and diligence focus: Evolocumab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 06, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03851263

Indication

Coronary Artery Disease

Modality

monoclonal antibody

Target

Evolocumab

Intervention

Evolocumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.